ClinicalTrials.gg
CompletedNCT05844852Updated Aug 31, 2026

P200TE US Reference Database Study

An interventional study of P200TE in Normal Eyes, sponsored by Optos, PLC. Completed at 9 sites in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Optos, PLC · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
954
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

The objective of this study is to collect Optical Coherence Tomography (OCT) data to construct a reference database for the P200TE.

Read the detailed description

The objective of this study is to collect Optical Coherence Tomography (OCT) data on healthy eyes in order to develop a reference database for the P200TE device in order to determine the reference limits for the P200TE

02

Conditions studied

  • Normal Eyes
03

In context

Lead sponsor

Optos, PLC is the lead sponsor of 18 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects 22 years of age or older on the date of
  2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  3. Subjects presenting at the site with normal eyes (Cataracts, LASIK, PRK (photorefractive keratectomy), and peripheral pathology that does not affect the posterior pole region, for example lattice and peripheral drusen, are allowed.
  4. BCVA (best corrected visual acuity) 20/40 or better(each eye)
  5. Subject is able to comply with the study procedures

Exclusion criteria

Exclusion Criteria:

  1. Subjects unable to tolerate ophthalmic imaging
  2. Subject has a condition or is in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
  3. Subject with ocular media not sufficiently clear toobtain acceptable OCT images
  4. .History of leukemia, dementia or multiple sclerosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
954 participants (actual)

Study arms

  • Other
    OCT

    Device: P200TE The P200TE provides OCT imaging including retina topography and ONH (optic nerve head) scans.

    Device: P200TE

Interventions

  • DeviceP200TE

    The P200TE provides OCT imaging including retinatopography and ONH (optic nerve head) scans.

06

What researchers measure

Primary outcomes

  1. Retinal Thickness

    The full thickness retina grid consists of a 9-sector circular grid pattern centered on the fovea and based on the ETDRS criteria.

    Time frame: 1 year

  2. GCC Thickness

    The GCC Thickness

    Time frame: 1 year

  3. RNFL Thickness

    The RNFL thickness

    Time frame: 1 year

  4. Optic Nerve Head

    The ONH size

    Time frame: 1 year

Secondary outcomes

  1. Adverse Events

    Number of any adverse events associated with the clinical study to ensure device safety.

    Time frame: 1 year

07

Study locations

9 sites
  • Marshall B Ketchum University, Southern California College of Optometry
    Anaheim, California 92807, United States
  • Werner Optometry
    San Diego, California 92019, United States
  • Eyecare of San Diego
    San Diego, California 92103, United States
  • Center for Sight
    Venice, Florida 34292, United States
  • Illinois College of Optometry
    Chicago, Illinois 60616, United States
  • New England College of Optometry
    Boston, Massachusetts 02215, United States
  • New England College of Optometry
    Roslindale, Massachusetts 02131, United States
  • State University of New York, Clinical Vision Research
    New York, New York 10036, United States
  • Specialty Eye Care Centre
    Bellevue, Washington 98004, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Sep 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2023
First posted
May 6, 2023
StartActual
Mar 14, 2023
Primary completionActual
Sep 13, 2023
CompletionActual
Sep 13, 2023
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05844852
Lead sponsor
Optos, PLC
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Mar 14, 2023
Primary completion
Sep 13, 2023
Completion
Sep 13, 2023
Last update
Aug 31, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion